Joint Developments, Drug Recommendations, and Milestone Achievements Highlight the Strong Potential of Biotechnology - Research

Joint Developments, Drug Recommendations, and Milestone Achievements Highlight
  the Strong Potential of Biotechnology - Research Report on Celgene, Onyx,
                   Cytokinetics, Dendreon, and ChemoCentryx

PR Newswire

NEW YORK, July 3, 2013

NEW YORK, July 3, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Wall Street Reports announced new research reports highlighting Celgene
Corporation (NASDAQ: CELG), Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX),
Cytokinetics, Incorporated (NASDAQ: CYTK), Dendreon Corp. (NASDAQ: DNDN), and
ChemoCentryx, Inc. (NASDAQ: CCXI). Today's readers may access these reports
free of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Celgene Corporation Research Report

On June 27, 2013, Celgene Corporation (Celgene) announced an agreement with
MorphoSys AG to jointly develop MOR202 globally and to co-promote MOR202 in
Europe. As per Celgene, MOR202 is a fully human monoclonal antibody targeting
CD38 to treat patients with multiple myeloma (MM) and certain leukemias, and
is currently being evaluated in a Phase 1/2a trial in patients with
relapsed/refractory myeloma. Mark Alles, Executive Vice President and Global
Head of Hematology and Oncology at Celgene, stated, "Strategic investments in
next generation medical innovation make it possible for physicians to turn
incurable cancers like multiple myeloma into chronic, more manageable
diseases." Alles added, "This collaboration with MorphoSys enables us to
rapidly advance a promising therapeutic antibody in a disease where
significant progress is being made, but where patients continue to need new
treatment options." The Full Research Report on Celgene Corporation -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.WSReports.com/r/full_research_report/7541_CELG]

--

Onyx Pharmaceuticals, Inc. Research Report

On June 30, 2013, Onyx Pharmaceuticals, Inc. (Onyx) affirmed that it has
received and also rejected an unsolicited proposal from Amgen Inc. (Amgen) for
the acquisition of all its outstanding shares and share equivalents for $120
per share in cash, subject to due diligence and other conditions. Dr. N.
Anthony Coles, Chairman and CEO of Onyx, commented, "Onyx has tremendous
momentum and, with the expansion of our pipeline and two successful product
launches, the Company and our talented employees have created significant
value for Onyx shareholders." Coles continued, "The Board and the management
team remain focused on the opportunities in front of us, including the
potential to expand the use of our existing therapies in different types of
cancer and across different lines of therapy, as a result of several ongoing
Phase 3 studies. We are actively exploring the potential to combine Onyx with
another company as an option to create additional value for Onyx
shareholders." The Full Research Report on Onyx Pharmaceuticals, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.WSReports.com/r/full_research_report/fcf8_ONXX]

--

Cytokinetics, Incorporated Research Report

On June 25, 2013, Cytokinetics, Incorporated (Cytokinetics) announced a
collaboration with Astellas Pharma Inc. (Astellas) focused on the R&D and
commercialization of skeletal muscle activators. Robert I. Blum, President and
CEO of Cytokinetics, said, "Through this collaboration, we intend to jointly
investigate the potential role that CK-2127107 and follow-on skeletal muscle
activators can play in providing functional improvements in patients with
diseases characterized by muscle weakness and fatigue. We are impressed with
Astellas' strategic vision and capabilities in the areas of novel mechanism
biopharmaceutical research and development." The Company stated that Astellas
will have the exclusive rights to develop and commercialize drug candidates
that may arise from these collaborative activities, subject to certain
Cytokinetics' development and commercialization rights. The Full Research
Report on Cytokinetics, Incorporated - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.WSReports.com/r/full_research_report/5a39_CYTK]

--

Dendreon Corp. Research Report

On June 28, 2013, Dendreon Corp. (Dendreon) announced that it has received a
positive opinion from the European Medicines Agency (EMA) Committee for
Medicinal Products for Human Use (CHMP), which recommended that Provenge
(autologous peripheral blood mononuclear cells activated with PAP-GM-CSF or
Sipuleucel-T) be granted a marketing authorization in the European Union (EU).
According to the Company, Provenge is to be used for the treatment of
asymptomatic or minimally symptomatic metastatic (non-visceral) castrate
resistant prostate cancer in male adults to whom chemotherapy is not yet
clinically indicated. John H. Johnson, Dendreon's Chairman, President, and
CEO, stated, "This recommendation represents a significant milestone for
Dendreon as we advance the global market opportunity for Provenge. We are
finalizing our plans for a capital-efficient launch in Europe, including
evaluating our partnering options. We look forward to bringing the innovative
treatment of PROVENGE to patients around the world." The Full Research Report
on Dendreon Corp. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.WSReports.com/r/full_research_report/d202_DNDN]

--

ChemoCentryx, Inc. Research Report

On June 19, 2013, ChemoCentryx, Inc. (ChemoCentryx) announced that it has
successfully completed its target enrollment of 270 patients in a Phase II
clinical trial in diabetic nephropathy with CCX140, an inhibitor of the
chemokine receptor known as CCR2 and the Company's lead wholly owned drug
candidate. Thomas J. Schall, PhD, ChemoCentryx's President and CEO, said, "We
are very pleased to have successfully completed this important Phase II
enrollment milestone with an over-enrollment of patients in the study. This
achievement will enable us to report 12-week data in approximately 200
patients in the third quarter of 2013, on track with our timeline
projections." Schall added, "As our most advanced wholly owned program, CCX140
is a key component of the ChemoCentryx pipeline targeting high-value
therapeutic areas with large unmet medical needs." The Full Research Report on
ChemoCentryx, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.WSReports.com/r/full_research_report/921e_CCXI]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Wall Street Reports

Contact: WSReports.com Phone #: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.